


RealRate

PHARMACEUTICAL 2021

BioXcel Therapeutics Inc. Rank 63 of 402









PHARMACEUTICAL 2021



RealRate

BioXcel Therapeutics Inc. Rank 63 of 402

The relative strengths and weaknesses of BioXcel Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BioXcel Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 89% points. The greatest weakness of BioXcel Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 234%, being 187% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	217,065
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,842
Liabilities, Non-Current	1,398
Other Assets	1,598
Other Compr. Net Income	0
Other Expenses	27
Other Liabilities	0
Other Net Income	0
Other Revenues	155
Property and Equipment	1,273
Research and Development	57,995
Selling, General and Administrative Expense	24,302

Output Variable	Value in 1000 USD
Assets	219,936
Liabilities	13,240
Expenses	82,324
Revenues	155
Stockholders Equity	206,696
Net Income	-82,169
Comprehensive Net Income	-82,169
Economic Capital Ratio	234%

